11 results about "Haemoglobin Suresnes" patented technology

The present invention relates to a method for determining a mortality risk and / or probability of a healthy lifespan of a dog; said method comprising determining the level of one or more biomarker(s) in one or more samples obtained from the dog, wherein the one or more biomarker(s) is selected from white blood cell count, serum albumin, serum alkaline phosphatase, serum creatine kinase, haemoglobin, haematocrit, mean corpuscular haemoglobin, serum glucose, mean red cell volume, serum globulin, serum calcium, platelet count, and / or red blood cell count.

The present disclosure relates to a staining reagent combination comprising a reagent A and a reagent B. The staining reagent combination is capable of simultaneously assessing total count of WBC, differential count of WBC and haemoglobin concentration from a biological sample in suspension form. The staining reagent combination is ideal for use in microfluidic platforms due to its high viscosity and lower volume required for measurement. The staining reagent combination is economical, non-toxic, has quick reaction and long working time.

A method of monitoring an analyte in blood, particularly glycated-haemoglobin (HbA1c or HgbA1c) using two photoplethysmocharty (PPG) sensors, which are worn on the body of a subject. Each photoplethysmocharty sensor observes blood of the subject in a different wavelength. One of the wavelengths monitors glycated-haemoglobin. The other one of the wavelengths monitors the body of blood in general. The shapes of the pulses obtained by each of the PPG sensor from the subject are used to adjust the intensity of the light emitted by the PPG sensors into the subject. If on adjustment of the light intensity, the shapes of the pulses become similar, the size of the pulses can be used to provide quasi-quantification of the analyte.

The present disclosure provides in vitro methods for identifying the presence or absence of haemoglobin S (HbS) or haemoglobin C (HbC) in a blood sample, kits and devices thereof. The inventors have found that HbS shows a substantial decrease in absorption under deoxygenated conditions compared to oxygenated conditions. The inventors expect HbC to show a similar decrease in absorption under deoxygenated conditions compared to oxygenated conditions. The methods, kits and devices of the disclosure employ this decrease in absorption under deoxygenated conditions to identify the presence or absence of HbS or HbC in a blood sample. The methods, kits and devices of the present disclosure are simple, low cost, and provide a rapid way to identify the presence or absence of HbS or HbC in a blood sample in a point-of-care setting.

The purpose of the present invention is to provide a medicine that is for use in instances of cyanide poisoning, hydrogen sulfide poisoning, and azide poisoning, that does not cause side effects, and that has excellent quick-acting properties and a high antidote effect. Specifically, the present invention is a medicine that is for use in instances of cyanide poisoning, hydrogen sulfide poisoning, and azide poisoning, and that contains, as an active ingredient, at least one selected from the group consisting of hemeproteins capable of binding to a cyanide ion (CN-), a hydrogen sulfide ion (HS-), and an azide ion (N3 -), hemeprotein-containing substances capable of binding to CN-, HS-, and N3 -, and heme derivatives capable of binding to CN-, HS-, and N3. More specifically, the present invention is a medicine or pharmaceutical composition for treatment or prophylaxis of cyanide poisoning, hydrogen sulfide poisoning, and azide poisoning.

The present invention relates to daprodustat or a pharmaceutically acceptable salt thereof for use in reducing fatigue in non-dialysis subjects with anemia associated with chronic kidney disease. In particular embodiments, the invention is directed to particular subject populations in which the subject has hsCRP≥6.60 mg / L at baseline and in which the subject has a haemoglobin concentration of ≤11 g / dL at baseline.

The present invention relates to an expression system for producing a recombinant haptoglobin (Hp) beta chain, or a haemoglobin-binding fragment thereof, recombinant Hp molecules and uses thereof for treating and / or preventing a condition associated with cell-free haemoglobin (Hb).

The present invention relates to a system for detecting diseases and providing healthcare services (100). The system (100) comprises of a plurality of handheld devices (102), a database (126) for storing data of patient and a software module (128). The handheld device (102) is configured to measure vital parameter of a patient's body through a plurality of sensors (110), wherein the plurality of sensor (110) includes a temperature sensor (112), a pulse oximeter sensor (114), a pulse sensor (116), a plurality of ECG leads (118), a blood pressure sensor (120). Additionally, the handheld device (102) may be interfaced to the glucometer and haemoglobin meter. The handheld device (102) is further configured to connect the user to a healthcare provider for consultation through a video call. Therefore, the present invention bridge the gap between rural patients and experienced medical professionals, thereby improving healthcare access for those in remote or underserved areas.

The present disclosure relates generally to methods of treating or preventing an adverse secondary neurological outcome in a subject following a haemorrhagic stroke accompanied by extravascular erythrolysis and release of cell-free heme and / or cell-free haemoglobin (Hb) into a cerebral spinal fluid (CSF), the method comprising exposing the CSF of a subject in need thereof to a therapeutically effective amount of hemopexin (Hx) and for a period of time sufficient to allow the Hx to form a complex with, and thereby neutralise, the cell-free heme and, optionally, exposing the CSF of the subject to a therapeutically effective amount of haptoglobin (Hp) and for a period of time sufficient to allow the Hp to form a complex with, and thereby neutralise, the cell-free Hb.

The present disclosure provides methods for determining optical absorbance of a blood sample, methods for identifying the presence or absence of sickle haemoglobin in a blood sample, kits and devices thereof The present methods comprise measuring a first absorbance of the blood sample under a deoxygenated condition at 420-440 nm and measuring a second absorbance of the blood sample under the deoxygenated condition at 541-570 nm. A ratio of the second absorbance to the first absorbance and a difference between the first absorbance and the second absorbance are calculated and employed to identify the presence or absence of sickle haemoglobin and determine the amount of sickle haemoglobin. The methods, kits and devices of the present disclosure are simple, low cost, and provide a rapid way to identify the presence or absence of and amount of sickle haemoglobin in a blood sample in a point-of-care setting.

The present invention relates to a method to determine the concentration of sickle-cell haemoglobin in blood. Said method is based on a smear technique involving drawing a smear at a particular speed, wherein the length of the smear is a function of the concentration of the HbS. It also provides a smear card having graduations to measure the smear length and the corresponding viscosity (in cP) and a device comprising such smear card; reducing agent and substrate.